Zura Bio Limited filings document the regulatory record of a Cayman Islands clinical-stage biotechnology company developing antibody candidates for autoimmune and inflammatory diseases. Its disclosures include operating and financial results, Regulation FD materials, clinical-program communications, and risk-related context for a multi-asset immunology pipeline led by tibulizumab (ZB-106).
The company’s SEC record also covers proxy governance matters, annual general meeting voting, executive and compensation arrangements, and capital-structure activity involving Class A ordinary shares, pre-funded warrants, underwriting agreements, and related legal opinions. Current reports and proxy materials provide formal disclosure of material events, shareholder matters, and emerging growth company status.
Zura Bio Limited may offer and sell up to $114,044,900 of Class A Ordinary Shares through an at-the-market offering under its amended sales agreement with Leerink Partners, after the registration statement becomes effective. The remaining capacity reflects $10,955,100 of prior sales against a $125,000,000 agreement limit. Leerink Partners will act as sales agent or principal, is not required to sell a specific amount, and earns a 3.0% commission on gross sales price per share.
At the assumed price of $3.56 per share, the prospectus illustrates 32,035,084 shares sold and estimates $1.32 of immediate dilution per share after commissions and estimated offering expenses. The base prospectus allows up to $700,000,000 in aggregate securities, with the ATM shares counted within that amount. Zura intends to use net proceeds for working capital, pipeline advancement and general corporate purposes. Its lead candidate, tibulizumab, is in Phase 2 clinical trials.
Zura Bio Limited reported a third-quarter 2026 net loss of $25.8 million, or $0.20 per share, compared with $18.0 million, or $0.21 per share, in third-quarter 2025. Research and development expense was $19.5 million, versus $11.9 million; the increase was primarily driven by continued Phase 2 tibulizumab programs and NEXUS-PMR start-up. General and administrative expense was $9.3 million, versus $7.6 million, primarily due to higher professional fees. Cash and cash equivalents were $187.7 million as of September 30, 2026, and Zura expects its existing cash to support planned operations through at least the end of 2028.
Enrollment is complete in two Phase 2 studies of investigational tibulizumab: TibuSHIELD randomized 247 participants with hidradenitis suppurativa, with topline data on track for Q4 2026, and TibuSURE randomized 91 participants with systemic sclerosis, with topline data on track for H1 2027. The FDA cleared NEXUS-PMR to proceed under an Investigational New Drug application, with initiation on track by year-end 2026. Tibulizumab has not been approved for marketing; Zura is evaluating development approaches for torudokimab and crebankitug.
Zura Bio Limited reported a net loss of $25.8 million for the third quarter of 2026 and $76.4 million for the first nine months, compared with $18.0 million and $51.5 million in the corresponding 2025 periods. Cash and cash equivalents were $187.7 million as of September 30, 2026. Based on current business plans, the company expects existing cash to fund operating expenses and capital requirements through at least the end of 2028.
Zura is advancing tibulizumab in Phase 2 studies. TibuSHIELD for hidradenitis suppurativa completed enrollment with 247 participants, with topline results expected in the fourth quarter of 2026; TibuSURE for systemic sclerosis completed enrollment with 91 participants, with topline results expected in the first half of 2027. An FDA-cleared IND supports planned initiation of a Phase 2 polymyalgia rheumatica study at year-end 2026. The company has no products approved for sale and has generated no product-sales revenue.
The February 2026 equity offering generated approximately $134.6 million in net proceeds after underwriting discounts, commissions and offering expenses. Net cash used in operating activities was $59.3 million for the first nine months of 2026.
Zura Bio Ltd (ZURA) received a notice under Rule 144 that director Someit Sidhu intends to sell common shares. The planned transaction involves 50,000 common shares through Morgan Stanley Smith Barney LLC, with an aggregate value of $287,712.50, currently associated with NASDAQ trading on 08/18/2026. The shares are tied to a stock option exercise for cash from the issuer on the same date. Over the prior three months, the same person reported additional sales of ZURA common stock.
Someit Sidhu, an affiliate of ZURA, has filed a notice of proposed sale of restricted or control securities. The filing covers a planned sale of 27,000 shares of common stock of ZURA on or about 08/17/2026, to be executed for cash through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, in connection with a stock option exercise. The notice also lists prior sales during the past three months totaling 40,000 shares for $220,540.00 on 08/14/2026 and 51,000 shares for $287,043.30 on 08/13/2026.
Zura Bio Limited furnished a corporate presentation dated August 17, 2026 for use at conferences and investor meetings. The presentation is included as Exhibit 99.1 and can be accessed via the News & Events section of the company’s investor relations website.
The information in this communication, including Exhibit 99.1, is furnished under Item 7.01 and is explicitly stated not to be deemed “filed” for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act, nor incorporated by reference into other SEC filings except where specifically referenced.
Someit Sidhu has filed to sell 40,000 shares of Common Stock of ZURA through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated aggregate value of $220,540.00, to be sold on or after August 14, 2026 on NASDAQ.
The filing also notes a prior stock option exercise on August 13, 2026 related to 40,000 shares and a separate sale of 51,000 shares of Common Stock on August 13, 2026 for $287,043.30.
Zura Bio Limited reported second quarter 2026 results and highlighted progress in its immunology pipeline centered on tibulizumab. Enrollment in both Phase 2 trials completed above target, with 247 participants in hidradenitis suppurativa (TibuSHIELD) and 91 in systemic sclerosis (TibuSURE). Topline data are expected in Q4 2026 and the first half of 2027, respectively, and a Phase 2 PMR study (NEXUS‑PMR) is planned by year-end 2026.
Cash and cash equivalents were $205.1 million as of June 30, 2026, up from $109.4 million at year-end 2025, and the company expects this to fund planned operations through at least the end of 2028. Second quarter 2026 R&D expense was $20.7 million and G&A expense was $8.6 million. Net loss for the quarter was $26.3 million, or $0.21 per share, compared with $16.0 million, or $0.17 per share, a year earlier. Shares outstanding were 95.4 million Class A ordinary shares as of June 30, 2026.
Zura Bio Limited is a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases, advancing lead antibody tibulizumab through Phase 2 trials in hidradenitis suppurativa and diffuse cutaneous systemic sclerosis, with additional programs in torudokimab and crebankitug under evaluation.
For the three months ended June 30, 2026, Zura reported a net loss of $26.3 million, and for the six months a net loss of $50.5 million, reflecting higher research and development spending as Phase 2 programs ramped. Research and development expenses rose to $20.7 million in the quarter and $35.5 million year-to-date, largely driven by tibulizumab clinical trial and manufacturing costs and increased R&D headcount. General and administrative expenses were $8.6 million in the quarter and $19.4 million for the six months.
Cash and cash equivalents were $205.1 million as of June 30, 2026, up from $109.4 million at year-end 2025, primarily due to the February 2026 equity offering, which generated approximately $134.6 million in net proceeds from issuing 21.2 million Class A Ordinary Shares and 1.8 million pre-funded warrants. Total assets were $213.4 million and shareholders’ equity $197.1 million, with management stating current liquidity is sufficient to fund operations through at least the end of 2028.